SARS-COV-2 VACCINATION AND REPORTING POLICY (UPDATE 1):
UNCLASSIFIED//
ROUTINE
R 311611Z MAR 21 MID200000756466U
FM CNO WASHINGTON DC
TO NAVADMIN
INFO SECNAV WASHINGTON DC
CNO WASHINGTON DC
BT
UNCLAS
NAVADMIN 070/21
MSGID/GENADMIN/CNO WASHINGTON DC/CNO/MAR//
SUBJ/SARS-COV-2 VACCINATION AND REPORTING POLICY (UPDATE 1)//
REF/A/DOC/DHA/DHA-IPM/13DEC2020//
REF/B/DOC/DOD/23JUL2019//
REF/C/DOC/32 CFR PART 199.21/01DEC2016//
REF/D/DOC/FDA/EUA/11DEC2020
REF/E/DOC/CDC/DOC/13DEC2020
REF/F/DOC/OUSD/12DEC2020
REF/G/MSG/OPNAV/042056ZNOV20
REF/H/DOC/OPNAV/04MAR2021
REF/I/MSG/OPNAV/161751ZDEC20
NARR/REF A IS THE DEFENSE HEALTH AGENCY INTERIM PROCEDURES MEMORANDUM
20-004 DEPARTMENT OF DEFENSE (DOD) CORONAVIRUS DISEASE 2019 (COVID-19)
VACCINATION IMPLEMENTATION PROGRAM.
REF B IS THE DODI 6025.02 INDIVIDUAL MEDICAL READINESS ADDRESSING
RESPONSIBILITIES AND PROCEDURES FOR MONITORING INDIVIDUAL MEDICAL READINESS.
REF C IS 32 CFR PART 199.21, CIVILIAN HEALTH AND MEDICAL PROGRAM OF THE
UNIFORMED SERVICES (CHAMPUS)/TRICARE: TRICARE PHARMACY BENEFITS PROGRAM.
REF D IS THE FOOD AND DRUG ADMINISTRATION EMERGENCY USE AUTHORIZATION (EUA).
REF E IS THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES INTERIM
RECOMMENDATION FOR USE OF PFIZER-BIONTECH COVID-19 VACCINE UNITED STATES,
DECEMBER 2020.
REF F IS THE DEPARTMENT OF DEFENSE CORONAVIRUS-2019 VACCINATION PLAN (DOD
COVID-19 VACCINE PLAN).
REF G IS THE U.S. NAVY COVID-19 STANDARDIZED OPERATIONAL GUIDANCE VERSION
4.0.
REF H IS THE UPDATED DOD AND NAVY POPULATION SCHEMA FOR VACCINATION PRIORITY
VERSION 3.4
REF I IS THE SARS-COV-2 VACCINATION AND REPORTING POLICY.// POC/ COVID-19
CRISIS ACTION TEAM /(703)681-1125/
EMAIL: usn.ncr.bumedfchva.mbx.bumed-2019-ncov-response-cell@mail.mil.
RMKS/1. This NAVADMIN updates vaccine eligibility for Service members and
their dependents executing an overseas permanent change of station (PCS).
This change is in accordance with the updated DOD Population Schema (REF H)
and modifies (REF I) to modify para 3.c and add para 3.g as follows:
Change paragraph 3.c:
Quote
3.c. SARS-CoV-2 Vaccine Priority. The basic DOD schema is:
Tier 1a: Healthcare and Emergency Service personnel.
Tier 1b: Critical national capabilities, personnel forward deployed to
austere locations, personnel preparing to deploy overseas, beneficiaries 75-
years-old and above.
Tier 1c: Beneficiaries between 64 and 75-years-old, high-risk beneficiaries,
personnel deployed/TDY OCONUS for over 30 days, essential workers not
previously mentioned.
Tier 2: Healthy uniformed personnel and population beneficiaries.
Unquote.
Change paragraph 3.c.1:
Quote:
3.c.1. Tier 1a is nearly complete. Tier 1b will extend through April 2021.
Tier 1c will begin in April. These dates are subject to change based on
vaccine production.
Unquote.
To lessen the burden on overseas MTFs, ease logistics chains regarding
overseas vaccine distribution, and aide Service members with navigating
widely disparate foreign requirements, add paragraph 3.g:
Quote
3.g. Service members and their eligible dependents will be prioritized to
receive the SARS-CoV-2 vaccine prior to executing an overseas PCS during the
overseas screening process at their affiliated MTF. Ensure vaccination
timeline incorporates full immunization prior to travel.
Unquote.
2. Released by VADM P. G. Sawyer, Deputy Chief of Naval Operations for
Operations, Plans and Strategy, OPNAV N3/N5.//
BT
#0001
NNNN
UNCLASSIFIED//